hERG Screening - Global Strategic Business Report

The global market for hERG Screening was valued at US$2.4 Billion in 2025 and is projected to reach US$5.9 Billion by 2032, growing at a CAGR of 13.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global hERG Screening Market - Key Trends & Drivers Summarized

Why Is hERG Screening Critical in Modern Drug Development Pipelines?

hERG (human Ether-à-go-go-Related Gene) screening is a crucial safety assay in drug discovery, used to evaluate a compound’s potential to block the cardiac potassium ion channel encoded by the KCNH2 gene. Inhibition of this channel can lead to QT interval prolongation and increase the risk of life-threatening cardiac arrhythmias such as Torsades de Pointes. As such, hERG screening has become a mandated component of preclinical safety pharmacology by global regulatory agencies including the FDA, EMA, and ICH.

Due to its implications for cardiac safety, hERG screening is essential not only for cardiovascular drugs but also for therapeutics across oncology, CNS, and infectious diseases. Drug candidates that show potential cardiotoxicity are typically modified, deprioritized, or withdrawn early in the pipeline, saving companies millions in downstream costs. This screening is also vital in lead optimization, enabling medicinal chemists to de-risk and refine compounds before entering animal or human studies.

How Are Technologies Advancing the Accuracy and Throughput of hERG Assays?

Recent advances in high-throughput screening (HTS), patch-clamp electrophysiology, and predictive computational modeling have significantly enhanced the precision and scalability of hERG testing. Automated planar patch-clamp platforms such as QPatch and SyncroPatch allow for high-content screening of ion channel activity with reduced labor and time investment. Similarly, fluorescence-based assays and voltage-sensitive dyes provide cost-effective alternatives for early-stage compound profiling.

In silico modeling and machine learning are now being applied to predict hERG liability based on chemical structure, reducing the need for exhaustive in vitro testing. The use of human iPSC-derived cardiomyocytes as a physiologically relevant platform for hERG evaluation is also gaining traction, especially under the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative. These technologies are improving predictability and regulatory alignment in preclinical cardiotoxicity assessment.

Which Sectors and Regions Are Leading hERG Screening Demand?

Pharmaceutical and biotechnology companies represent the primary end-users of hERG screening, integrating these assays during early preclinical development and regulatory submission phases. CROs (Contract Research Organizations) are also major providers of hERG screening services, offering scalable, outsourced assay capabilities to drug developers. Academic institutions and toxicology research labs utilize hERG models for cardiac safety evaluation and channelopathy research.

Geographically, North America dominates the hERG screening market, driven by intensive drug development activity, stringent regulatory requirements, and advanced laboratory infrastructure. Europe follows, with a strong focus on regulatory science and public-private drug development collaborations. Asia-Pacific is emerging as a high-growth region, especially China and India, where pharmaceutical R&D spending is rising and global drugmakers are outsourcing early toxicology studies.

The Growth in the hERG Screening Market Is Driven by Several Factors

The growth in the hERG screening market is driven by several factors related to safety pharmacology mandates, drug development complexity, and technology-driven screening innovation. Advances in automated patch-clamp systems, human-relevant cell models, and predictive AI-based screening tools have significantly enhanced throughput, accuracy, and regulatory compliance. These innovations are reducing time-to-decision for drug safety profiling while minimizing clinical failure risks.

On the end-use side, the expanding global pharmaceutical pipeline, especially in oncology and CNS drugs, is increasing the volume of compounds requiring hERG liability testing. The rise of personalized medicine and targeted therapies further necessitates precise cardiotoxicity screening. Regulatory frameworks like ICH S7B and the CiPA initiative continue to emphasize hERG as a primary biomarker of cardiac safety, ensuring that it remains integral to preclinical workflows. As safety standards and development timelines grow increasingly stringent, hERG screening is becoming indispensable in de-risking and accelerating new drug development.

Report Scope

The report analyzes the hERG Screening market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (Gene KCNH2 Type, Mutant KCNH2 Type); Ion Channel (Voltage-Gated Ion Channel, Ligand-Gated Ion Channel); Application (Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application, Other Applications)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Gene KCNH2 Type segment, which is expected to reach US$4.4 Billion by 2032 with a CAGR of a 14.9%. The Mutant KCNH2 Type segment is also set to grow at 10.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $654.8 Million in 2025, and China, forecasted to grow at an impressive 18.0% CAGR to reach $1.3 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global hERG Screening Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global hERG Screening Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global hERG Screening Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as ApconiX Ltd., Aurigene Pharmaceutical Services, Charles River Laboratories, Creative Bioarray, Cyprotex (Evotec) and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this hERG Screening market report include:

• ApconiX Ltd.
• Aurigene Pharmaceutical Services
• Charles River Laboratories
• Creative Bioarray
• Cyprotex (Evotec)
• Eurofins Discovery
• Evotec SE
• Mediford
• Metrion Biosciences
• Molecular Devices
• Reaction Biology Corporation
• Thermo Fisher Scientific
• WuXi AppTec
• Eurofins Discovery
• Charles River Laboratories
• ApconiX Ltd.
• Creative Bioarray
• Cyprotex (Evotec)
• Mediford
• Metrion Biosciences

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.